Acurx Pharmaceuticals (ACXP) to Release Quarterly Earnings on Tuesday
by Teresa Graham · The Cerbat GemAcurx Pharmaceuticals (NASDAQ:ACXP – Get Free Report) is expected to issue its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.59) per share for the quarter. Parties can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 8:00 AM ET.
Acurx Pharmaceuticals (NASDAQ:ACXP – Get Free Report) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($1.01) by $0.70. On average, analysts expect Acurx Pharmaceuticals to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Acurx Pharmaceuticals Price Performance
Shares of NASDAQ:ACXP traded down $0.05 during trading hours on Tuesday, hitting $2.09. The company’s stock had a trading volume of 9,925 shares, compared to its average volume of 2,295,595. Acurx Pharmaceuticals has a 52 week low of $1.33 and a 52 week high of $21.00. The company has a market capitalization of $5.96 million, a price-to-earnings ratio of -0.37 and a beta of -2.09. The firm’s fifty day moving average price is $3.02 and its 200 day moving average price is $3.47.
Analyst Upgrades and Downgrades
ACXP has been the subject of several recent research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a report on Monday, April 20th. Wall Street Zen upgraded shares of Acurx Pharmaceuticals to a “sell” rating in a report on Saturday, April 25th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $31.00.
Get Our Latest Stock Analysis on Acurx Pharmaceuticals
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the stock. Armistice Capital LLC acquired a new position in Acurx Pharmaceuticals during the 2nd quarter valued at approximately $551,000. Millennium Management LLC acquired a new position in Acurx Pharmaceuticals during the 4th quarter valued at approximately $103,000. Geode Capital Management LLC acquired a new position in Acurx Pharmaceuticals during the 4th quarter valued at approximately $31,000. Finally, Jane Street Group LLC acquired a new position in Acurx Pharmaceuticals during the 4th quarter valued at approximately $27,000. Institutional investors and hedge funds own 11.53% of the company’s stock.
About Acurx Pharmaceuticals
Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.
Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).